AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD

2025-12-15 14:50:59 ET

The last time I spoke about AC Immune ( ACIU ), it was with respect to a Seeking Alpha article entitled " AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward ". With respect to this article, I noted that the company was in the process of developing its anti-Abeta active immunotherapy candidate ACI-24.060 with its partner Takeda Pharmaceutical Company Limited ( TAK ) to treat patients with Alzheimer's Disease [AD] and in non-demented adults with Down Syndrome in the ongoing Phase 2 ABATE trial. This collaboration is ideal because AC Immune was able to receive a $100 million upfront payment for this collaboration of advancing ACI-24.060 and is eligible to earn up to $2.1 billion in milestone payments as well. As an update for this program, the 12-month treatment timepoint for the AD3 cohort as part of this study is expected to be reached by year-end. The importance of this is that interim results are to be released after such time; thus, data could come in Q4 of 2025 or slip a bit into early 2026....

Read the full article on Seeking Alpha

For further details see: